Business

Travere Therapeutics Rallies To Buy Point As Kidney Drug Sales Rocket 182%; Anticipates FDA Priority Review For FSGS Treatment

May 6, 2025 - 18:00
 0
Travere Therapeutics Rallies To Buy Point As Kidney Drug Sales Rocket 182%; Anticipates FDA Priority Review For FSGS Treatment
Read More

Related Posts

DOGE says IRS modernization program is $15B over budget and 30 years overdue

DOGE says IRS modernization program is $15B over budget...

Mar 21, 2025  2

ZipRecruiter SVP Bartolome Lora sells $12,861 in shares

ZipRecruiter SVP Bartolome Lora sells $12,861 in shares

Mar 21, 2025  1

Dream Finders Homes director Lovett sells $2.65 million in stock

Dream Finders Homes director Lovett sells $2.65 million...

Mar 21, 2025  0

Elon Musk says DOGE cuts necessary, but face headwinds according to Fox poll

Elon Musk says DOGE cuts necessary, but face headwinds ...

Mar 21, 2025  0

Elon Musk reassures Tesla workers with all-hands meeting, admits it 'feels like Armageddon'

Elon Musk reassures Tesla workers with all-hands meetin...

Mar 21, 2025  3

ZipRecruiter CTO Boris Shimanovsky sells $22,788 in stock

ZipRecruiter CTO Boris Shimanovsky sells $22,788 in stock

Mar 21, 2025  0